Description:
Polmacoxib is the first tissue specific selective COX-2 inhibitor indicated for the treatment of idiopathic osteoarthritis of hip and knee. It has a mechanism of action which involves dual inhibition of COX-2 enzymes and carbonic anhydrase (CA) I/II. The dual mode of action exhibited by polmacoxib is expected to minimize adverse cardiovascular effects while achieving maximum effectiveness in inflamed osteoarthritic joints. Polmacoxib has demonstrated superior efficacy to placebo and noninferior to celecoxib after 6 weeks. It has a long-term safety profile of 24 weeks.
Share your experience with our medical product. Write a review!
22 Jul 2026
International Yoga Day 2026: How Yoga Promotes Wellness, Wisdom & Inner Peace
Yoga is more than a form of physical exercise. It is a holistic practice that connects the body, mind, and breath to support overall wellbeing. Every year, International Yoga Day encourages people aro
15 Jul 2026
World Brain Tumor Day 2026: Early Detection Awareness and the Need to Reduce Diagnostic Delays
World Brain Tumor Day is observed annually on 8 June to raise awareness about brain tumours, encourage early diagnosis, and support patients and families affected by these complex conditions.
15 Jun 2026
Hetero Healthcare on World No Tobacco Day 2026 - Unmasking the Appeal, Countering Addiction
Every year on May 31, the world comes together to observe World No Tobacco Day, a global initiative aimed at raising awareness about the dangers of tobacco use.
01 Jun 2026
Salt, Stress, and Sedentary Life: The Three Big Triggers of Hypertension
Every two seconds, somewhere in the world, a person suffers a heart attack or stroke linked to uncontrolled blood pressure.
